ArticleBiomolecules2026
Loss of p53 Provokes NF-κB-Dependent Disruption of Nucleolar Cap and Nucleoplasmic Redistribution of Fibrillarin During Nucleolar Stress.
Takeru Torii, Mako Sumida, Atsushi Kobayashi, Toshiyuki Goto, Ryosuke Suzuki, Shin Kuwamoto, Wataru Nakajima, Wataru Sugimoto, Kohei Takeuchi, Yuma Tanaya and 8 more
Abstract read
In one paragraphArticle in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Takeru ToriiFaculty of Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Hyōgo, Japan.ORCID 0000-0002-6278-7617 Mako SumidaFaculty of Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Hyōgo, Japan.
Atsushi KobayashiFaculty of Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Hyōgo, Japan.
Toshiyuki GotoFaculty of Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Hyōgo, Japan.ORCID 0000-0002-2827-4199 Ryosuke SuzukiFaculty of Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Hyōgo, Japan.
Shin KuwamotoFaculty of Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Hyōgo, Japan.ORCID 0000-0002-2513-5222 Wataru NakajimaDepartment of Molecular Oncology, Institute for Advanced Medical Sciences, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku 113-8602, Tokyo, Japan.
Wataru SugimotoFaculty of Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Hyōgo, Japan.ORCID 0000-0002-7381-1862 Kohei TakeuchiFaculty of Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Hyōgo, Japan.
Yuma TanayaDepartment of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Naka-cho, Koganei 184-8588, Tokyo, Japan.
Masayuki TeraDepartment of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Naka-cho, Koganei 184-8588, Tokyo, Japan.ORCID 0000-0003-4430-579X Nobuyuki TanakaDepartment of Molecular Oncology, Institute for Advanced Medical Sciences, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku 113-8602, Tokyo, Japan.ORCID 0000-0002-6373-2220 Hiroaki HirataDepartment of Life Science and Biotechnology, Kanazawa Institute of Technology, Hakusan 924-0838, Ishikawa, Japan.ORCID 0000-0002-2604-9158 Hisae Tateishi-KarimataFaculty of Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Hyōgo, Japan.ORCID 0000-0001-6161-9817 Takahito NishikataFaculty of Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Hyōgo, Japan.ORCID 0000-0002-2965-1793 Miwako Kato HommaDepartment of Biomolecular Sciences, Fukushima Medical University School of Medicine, Hikarigaoka, Fukushima 960-1295, Fukushima, Japan.
Daisuke MiyoshiFaculty of Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Hyōgo, Japan.ORCID 0000-0002-4308-0499 Keiko KawauchiFaculty of Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Hyōgo, Japan.ORCID 0000-0002-8276-7277 Funding
JSPS KAKENHI 19J21096JSPS KAKENHI 20K21259JSPS KAKENHI 21H02062JSPS KAKENHI 21K06158JSPS KAKENHI 24K21801JST SPRING JPMJSP2117
6 · The paper itselfAbstract
Chemotherapeutic agents targeting ribosome biogenesis induce profound reorganization of nucleolar architecture, yet how the tumor suppressor p53 governs these structural responses remains unclear. Here, we show that loss of p53 leads to NF-κB-dependent disappearance of nucleolar caps induced by doxorubicin (DOXO). Under these conditions, fibrillarin (FBL), which is normally confined to the nucleolus, relocates to the nucleoplasm and forms foci that partially associate with G-quadruplex (G4) structures, non-canonical nucleic acid secondary structures enriched at transcriptionally active genomic regions. To examine whether this redistribution is linked to transcriptional changes, we integrated publicly available transcriptomic datasets and identified genes that were upregulated in p53-deficient cells under DOXO treatment and downregulated upon FBL depletion. Given that casein kinase 2 alpha (CK2α) is a nuclear binding partner of FBL, we further analyzed CK2α-dependent gene programs. This analysis revealed that a fraction of FBL-responsive genes overlapped with CK2α-dependent signatures and were enriched for promoter-proximal G4 structures. Among candidate regulators, the G4-binding transcription factor MAZ emerged as a potential mediator linking nucleoplasmic FBL and CK2α to G4-associated transcriptional regulation. Together, our findings identify a mechanism linking loss of p53 to G4-associated transcriptional reprogramming through nucleolar architectural disruption mediated by an FBL-CK2α-MAZ axis during DOXO treatment.
Indexed as
Cell NucleolusChromosomal Proteins, Non-HistoneNF-kappa BTumor Suppressor Protein p53Casein Kinase IICell NucleusDoxorubicinG-QuadruplexesHumansCasein Kinase IIChromosomal Proteins, Non-HistoneDoxorubicinfibrillarinNF-kappa BTumor Suppressor Protein p53fibrillaringene expressionG-quadruplexNF-κBnucleolar stressp53
Identifiers
PMID41750364
PMCPMC12937983
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390